Background The COVID-19 pandemic has claimed the lives of nearly 2 million people
worldwide. 1 Following rapid sequencing of SARS-CoV-2, pharmaceutical companies and …

Recent data suggest that inflammatory bowel disease (IBD) patients do not receive
preventive services at the same rate as general medical patients. Patients with IBD often …

Objective To evaluate the relation between intake of ultra-processed food and risk of
inflammatory bowel disease (IBD). Design Prospective cohort study. Setting 21 low, middle …

Background The effects that therapies for inflammatory bowel disease (IBD) have on
immune responses to SARS-CoV-2 vaccination are not yet fully known. Therefore, we …

Objective Delayed second dose SARS-CoV-2 vaccination trades maximal effectiveness for a
lower level of immunity across more of the population. We investigated whether patients with …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

Background & Aim Patients with inflammatory bowel diseases (IBD), specifically those
treated with anti–tumor necrosis factor (TNF) α biologics, are at high risk for vaccine …

SARS-CoV-2 has caused a global health crisis and mass vaccination programmes provide
the best opportunity for controlling transmission and protecting populations. Despite the …

6.1. Background The incidence of tuberculosis (TB) is a concern at the start of the third
millennium, particularly with the increase of multiresistant (MDR-TB) and extended resistant …

Background & Aims Vaccination against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has rapidly expanded; however, clinical trials excluded patients taking …